Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.080
+0.010 (0.93%)
May 2, 2025, 4:00 PM EDT - Market closed
Acumen Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
65.42M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.19B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
ABOS News
- 4 weeks ago - Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - GlobeNewsWire
- 5 weeks ago - Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - GlobeNewsWire
- 6 weeks ago - Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's - GlobeNewsWire
- 7 weeks ago - Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting - GlobeNewsWire
- 7 weeks ago - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - GlobeNewsWire
- 6 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript - Seeking Alpha